Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.68 |
| ▸ | PNP | P00491 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.68 |
| ▸ | NT5E | P21589 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.53 |
| ▸ | PDE2A | O00408 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24220709 | 1.00 | PDE4D (0.68) | PDE4DPDE3APNPLMNATP53 | |
| SCHEMBL23474144 | 1.00 | PDE4D (0.68) | PDE4DPDE3APNPLMNATP53 | |
| SCHEMBL4452532 | 0.89 | PDE4D (0.68) | PDE4DPDE3APNPLMNATP53 | |
| SCHEMBL17364309 | 0.88 | PDE4D (0.67) | PDE4DPDE3APNPLMNATP53 | |
| SCHEMBL25619590 | 0.88 | PNP (0.52) | PDE4DPDE3APNPLMNATP53 | |
| SCHEMBL25619505 | 0.88 | PNP (0.52) | PDE4DPDE3APNPLMNATP53 | |
| SCHEMBL21088897 | 0.86 | PDE4D (0.73) | PDE4DPDE3APNPLMNATP53 | |
| SCHEMBL21089006 | 0.86 | PDE4D (0.73) | PDE4DPDE3APNPLMNATP53 | |
| SCHEMBL10015808 | 0.86 | PDE4D (0.73) | PDE4DPDE3APNPLMNATP53 | |
| SCHEMBL12746288 | 0.84 | PDE4D (0.68) | PDE4DPDE3APNPLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192750-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2023-06-22 | — | — | US | disclosed |
| US-11560400-B2 | Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds | NuCana plc (GB) | 2023-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192750-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NUDT1, TYMP, NTPCR | PDE4D 924/4885PDE3A 2093/4885PNP 8/4885 |
| US-11560400-B2 | Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds | NUDT1, NTPCR, TYMP | PDE4D 918/4885PDE3A 2030/4885PNP 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.